<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T08:05:03Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/10245" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/10245</identifier><datestamp>2024-12-13T10:57:29Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)</dc:title>
   <dc:creator>Garcia-Saenz, Jose Angel</dc:creator>
   <dc:creator>Blancas, Isabel</dc:creator>
   <dc:creator>Echavarria, Isabel</dc:creator>
   <dc:creator>HINOJO, CARMEN</dc:creator>
   <dc:creator>Margeli Vila, Mireia</dc:creator>
   <dc:creator>Moreno, Fernando</dc:creator>
   <dc:creator>Bellet Ezquerra, Meritxell</dc:creator>
   <dc:subject>Mama - Càncer - Tractament</dc:subject>
   <dc:subject>Mama - Càncer - Aspectes genètics</dc:subject>
   <dc:subject>Resistència als medicaments</dc:subject>
   <dc:subject>Qualitat de vida</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms</dc:subject>
   <dc:subject>PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance</dc:subject>
   <dc:subject>DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics</dc:subject>
   <dc:subject>HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life</dc:subject>
   <dc:subject>ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama</dc:subject>
   <dc:subject>FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos</dc:subject>
   <dc:subject>DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::biología computacional::genómica</dc:subject>
   <dc:subject>ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida</dc:subject>
   <dcterms:abstract>Advanced breast cancer; Anti-HER2 therapy; Endocrine therapy</dcterms:abstract>
   <dcterms:abstract>Càncer de mama avançat; Teràpia anti-HER2; Teràpia endocrina</dcterms:abstract>
   <dcterms:abstract>Cáncer de mama avanzado; Terapia anti-HER2; Terapia endocrina</dcterms:abstract>
   <dcterms:abstract>Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.</dcterms:abstract>
   <dcterms:dateAccepted>2023-11-08T10:23:22Z</dcterms:dateAccepted>
   <dcterms:available>2023-11-08T10:23:22Z</dcterms:available>
   <dcterms:created>2023-11-08T10:23:22Z</dcterms:created>
   <dcterms:issued>2023-09-06T11:10:28Z</dcterms:issued>
   <dcterms:issued>2023-09-06T11:10:28Z</dcterms:issued>
   <dcterms:issued>2023-09</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>http://hdl.handle.net/11351/10245</dc:identifier>
   <dc:relation>Clinical and Translational Oncology;25</dc:relation>
   <dc:relation>https://doi.org/10.1007/s12094-023-03203-8</dc:relation>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>Springer</dc:publisher>
   <dc:source>Scientia</dc:source>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>